A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Trial Profile

A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTA
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Results of analysis assessing use of MAIC to indirectly compare progression-free survival (PFS) and overall survival (OS) using patient data from ALTA, ASCEND I, ASCEMD 2 and NP28673 trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results describing patient-reported outcomes and quality of life from this trial presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results assessing the safety and efficacy of Brigatinib in patients with crizotinib refractory advanced ALK+ non-small cell lung cancer (NSCLC) and brain metastases, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top